BRISTOL MYERS SQUIBB CO
BMY · CIK 0000014272 · Pharmaceutical Preparations
About BRISTOL MYERS SQUIBB CO
In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.
Business information sourced from SEC annual filing filed Feb 11, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 31, 2025 | $48.19B | $7.05B | — | $90.04B | $71.53B | $10.21B | $14.16B | 14.6% |
| Dec. 31, 2024 | $48.30B | −$8.95B | — | $92.60B | $76.22B | $10.35B | $15.19B | -18.5% |
| Dec. 31, 2023 | $45.01B | $8.02B | — | $95.16B | $65.67B | $11.46B | $13.86B | 17.8% |
| Dec. 31, 2022 | $46.16B | $6.33B | — | $96.82B | $65.70B | $9.12B | $13.07B | 13.7% |
| Dec. 31, 2021 | $46.38B | $6.99B | — | $109.31B | $73.31B | $13.98B | $16.21B | 15.1% |
| Dec. 31, 2020 | $42.52B | −$9.02B | — | $118.48B | $80.60B | $14.55B | $14.05B | -21.2% |
| Sept. 30, 2020 | — | — | — | $125.54B | — | $19.44B | — | — |
| June 30, 2020 | — | — | — | $128.08B | — | $19.93B | — | — |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- BRISTOL MYERS SQUIBB CO
- Ticker symbol
- BMY
- CIK
- 0000014272
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC SIC code
- 2834
- Fiscal year end (MMDD)
- 1231
- Last SEC synchronization
- Nov 7, 2026 19:21 UTC
- Headquarters / business address
- ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543 - Mailing address
- ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543 - Business phone
- 6092524621
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:26 UTC. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 4 | Nov. 6, 2026 | Nov. 5, 2026 | View SEC filing ↗ |
| 4 | Nov. 4, 2026 | Nov. 3, 2026 | View SEC filing ↗ |
| 4 | Nov. 3, 2026 | Nov. 1, 2026 | View SEC filing ↗ |
| 4 | Nov. 3, 2026 | Nov. 1, 2026 | View SEC filing ↗ |
| 4 | Nov. 3, 2026 | Nov. 1, 2026 | View SEC filing ↗ |
| 4 | Oct. 5, 2026 | Oct. 2, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Sept. 30, 2026 | View SEC filing ↗ |
| 4 | Sept. 10, 2026 | Sept. 9, 2026 | View SEC filing ↗ |
| 4 | Sept. 3, 2026 | Sept. 1, 2026 | View SEC filing ↗ |
| 4 | Aug. 26, 2026 | Aug. 25, 2026 | View SEC filing ↗ |
| 4 | Aug. 4, 2026 | Aug. 1, 2026 | View SEC filing ↗ |
| 4 | Aug. 4, 2026 | Aug. 1, 2026 | View SEC filing ↗ |
| 4 | July 2, 2026 | June 30, 2026 | View SEC filing ↗ |
| 4 | July 2, 2026 | June 30, 2026 | View SEC filing ↗ |
| 4 | July 2, 2026 | June 30, 2026 | View SEC filing ↗ |
| 4 | July 2, 2026 | June 30, 2026 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.